University of Miami Living Legends in Psychopharmacology 2026

University of Miami Living Legends in Psychopharmacology 2026 is an advanced, evidence-based psychiatry and psychopharmacology conference focusing on the latest developments in precision psychiatry, clinical neuroscience, personalized psychiatric treatment, artificial intelligence (AI), and emerging therapies for complex and treatment-resistant psychiatric disorders.

Organized by the University of Miami Miller School of Medicine, Department of Psychiatry and Behavioral Sciences, this two-day educational program brings together internationally recognized experts in psychiatry, neuroscience, psychiatric pharmacology, and mental health research.

The conference explores innovative approaches to diagnosing and treating major depressive disorder, bipolar disorder, schizophrenia, anxiety disorders, post-traumatic stress disorder (PTSD), autism spectrum disorder, sleep disorders, and substance use disorders.

Through expert lectures, research-based discussions, and interactive faculty panels, participants examine how recent advances in pharmacogenomics, neurobiology, digital phenotyping, neuromodulation, and AI-assisted clinical decision-making can improve individualized psychiatric care.

Course Details

The university’s official conference listing confirms the dates, program, and original CME designation. CME credit for a separately distributed recording is not established by the live conference accreditation.

Target Audience

This educational activity is designed for practicing clinicians and healthcare professionals involved in psychopharmacology and mental health treatment.

• Psychiatrists: Physicians managing mood disorders, schizophrenia, treatment-resistant depression, and complex psychiatric conditions.

• Psychiatric Nurse Practitioners: Advanced practice professionals involved in psychiatric medication management and patient-centered care.

• Psychologists: Mental health specialists interested in the neurobiological and pharmacological foundations of psychiatric treatment.

• Internal Medicine Physicians: Clinicians caring for patients with psychiatric comorbidities and complex medication regimens.

• Neurologists: Specialists interested in the relationship between neuroscience, psychiatric symptoms, and neuropsychiatric disorders.

• Psychiatry Residents and Fellows: Trainees seeking advanced knowledge in clinical psychopharmacology and emerging psychiatric therapies.

• Nurses and Physician Assistants: Professionals contributing to psychiatric assessment, therapeutic monitoring, and multidisciplinary care.

• Clinical Researchers: Scientists investigating neuroscience, pharmacogenomics, psychiatric drug development, and AI-assisted mental healthcare.

Program Overview

Living Legends in Psychopharmacology 2026 examines the rapidly evolving intersection of neuroscience, precision medicine, and psychiatric therapeutics.

As clinical psychiatry advances toward individualized treatment strategies, healthcare professionals require a deeper understanding of how genetic variation, pharmacokinetics, neurocircuitry, inflammation, and emerging technologies influence psychiatric diagnosis and therapeutic response.

The conference emphasizes personalized psychopharmacology, including pharmacogenomic considerations, psychotropic medication sequencing, dose optimization, and treatment selection for patients with complex or treatment-resistant psychiatric illnesses.

Participants also explore developments in somatic and emerging therapies, including psychedelics, neuromodulation, and innovative approaches to difficult-to-treat mood disorders.

Specialized sessions address psychiatric treatment across the lifespan, including pediatric and adolescent psychopharmacology, women’s reproductive mental health, geriatric psychiatry, and autism spectrum disorders.

The program further examines sleep disorders, co-occurring psychiatric and substance use disorders, benzodiazepine prescribing, and the ethical implications of incorporating artificial intelligence into psychiatric practice.

By integrating foundational neurobiology with emerging research and clinical applications, the conference supports evidence-based, individualized, and patient-centered psychiatric treatment.

Learning Objectives

Upon completion of this educational activity, participants should be able to:

1. Apply principles of personalized psychiatry to optimize psychotropic medication regimens in treatment-resistant patients.

2. Evaluate and implement evidence-based use of cutting-edge therapies.

3. Integrate current neurobiological insights into the diagnosis and treatment planning of complex psychiatric conditions.

4. Select and sequence appropriate pharmacologic and somatic treatments for major depressive disorder, schizophrenia, and bipolar disorder.

5. Translate emerging clinical research into practical decision-making tools for the treatment of complex psychiatric cases.

6. Formulate individualized treatment plans for anxiety disorders and PTSD.

7. Design safe and effective psychopharmacologic treatment strategies for women across the reproductive lifespan.

8. Interpret and apply recent findings in pediatric, adolescent, and geriatric psychiatry to inform age-appropriate diagnosis, medication selection, and monitoring strategies.

9. Assess and treat autism spectrum disorders using advanced pharmacologic approaches.

10. Diagnose and manage sleep disorders and substance use disorders with a focus on neurobiological mechanisms, risk mitigation, and integrated pharmacologic and behavioral treatments.

11. Translate emerging clinical research into practical decision-making tools for the treatment of complex psychiatric cases.

12. Demonstrate enhanced clinical communication and therapeutic alliance skills that support adherence, safety, and patient-centered care in psychopharmacologic practice.

13. Analyze the ethical implications of integrating artificial intelligence in psychiatric care, focusing on data privacy, algorithmic biases, and the preservation of the therapeutic alliance, while identifying strategies to ensure that AI tools enhance, rather than replace, patient-centered care.

The original learning objectives are retained, including the repeated objective on translating clinical research into practical decision-making.

Official Program Topics and Faculty

The following agenda is based on the University of Miami’s published 2026 conference schedule, preserving the session subjects, assigned faculty, and presentation times.

Day 1 — Friday, April 17, 2026

Psychiatric Neuroscience, Lifespan Psychopharmacology, and Emerging Treatments

8:15 AM – 8:30 AM

Welcome and Overview

Faculty: Barbara J. Coffey, MD, MS

8:30 AM – 9:15 AM

From Synapse and Symptom to Disease: Nosology and Pathogenesis as the Foundation for Psychiatric Treatment

Speaker: Nassir Ghaemi, MD, MPH

9:15 AM – 10:00 AM

Young Brains: Current Evidence and Innovations in Pediatric and Adolescent Psychopharmacology

Speaker: Barbara J. Coffey, MD, MS

10:00 AM – 10:30 AM

Coffee Break

10:30 AM – 11:15 AM

Hormones and the Mind: Psychopharmacology Across the Female Reproductive Lifespan

Speaker: Ariadna Forray, MD

11:15 AM – 12:00 PM

Caring for the Aging Mind: Psychopharmacologic Approaches in Geriatric Psychiatry

Speaker: Elizabeth Crocco, MD

12:00 PM – 12:45 PM

Panel Discussion: Faculty and Audience

Panelists:

• Giuliana Altare, DNP, APRN, PMHNP-BC

• Elizabeth Crocco, MD

• Nassir Ghaemi, MD, MPH

• Barbara J. Coffey, MD, MS

• Ariadna Forray, MD

12:45 PM – 2:00 PM

Lunch (On Your Own)

2:00 PM – 2:45 PM

Advances in Psychopharamcology Treatments in Serious Mental Illness: Decoding the Breadth of Treatment Effects with Accessible Digital Phenotyping

Speaker: Philip Harvey, PhD

2:45 PM – 3:30 PM

Beyond Behavior: Pharmacologic and Neurobiological Advances in Treating Autism Spectrum Disorder

Speaker: Alexander Kolevzon, MD

3:30 PM – 3:44 PM

Coffee Break

3:45 PM – 4:30 PM

From Mesmer to Psychodelics: Appreciating the Contributions of Contextual Factors to Treatment Response

Speaker: Gerard Sanacora, MD, PhD

4:30 PM – 5:30 PM

Panel Discussion: Faculty and Audience

Panelists:

• Giuliana Altare, DNP, APRN, PMHNP-BC

• Gerard Sanacora, MD, PhD

• Barbara J. Coffey, MD, MS

• Philip Harvey, PhD

• Alexander Kolevzon, MD

Day 2 — Saturday, April 18, 2026

Precision Psychiatry, Artificial Intelligence, Mood Disorders, Sleep, and Addiction

8:30 AM – 9:15 AM

Personalizing Psychopharmacology through Genetics and Artificial Intelligence

Speaker: Daniel Weinberger, MD

9:15 AM – 10:00 AM

New Vista in the Treatment of Mood and Anxiety Disorders: Psychedelics, Neuromodulation and More

Speaker: Charles Nemeroff, MD, PhD

10:00 AM – 10:30 AM

Coffee Break

10:30 AM – 11:15 AM

Depression Decoded: Inflammation, Neurocircuitry, and Breakthrough Treatments for Difficult-to-Treat Mood Disorders

Speaker: Alan Schatzberg, MD

11:15 AM – 12:00 PM

Navigating the Future: Ethical Challenges and Considerations of Artificial Intelligence in Psychiatric Care

Speaker: Azizi Seixas, PhD

12:00 PM – 12:45 PM

Panel Discussion: Faculty and Audience

Panelists:

• Giuliana Altare, DNP, APRN, PMHNP-BC

• Charles Nemeroff, MD, PhD

• Daniel Weinberger, MD

• Luca Pani, MD

• Alan Schatzberg, MD

• Azizi Seixas, PhD

12:45 PM – 2:00 PM

Lunch (On Your Own)

2:00 PM – 2:45 PM

Restoring Rest: Neurobiological and Pharmacologic Strategies for Sleep Disorders in Psychiatric Practice

Speaker: Sogol Javaheri, MD, MPH

2:45 PM – 3:30 PM

Dual Diagnosis in Focus: Treating Co-Occurring Psychiatric and Substance Use Disorders

Speaker: Roger D. Weiss, MD

3:30 PM – 3:45 PM

Coffee Break

3:45 PM – 4:30 PM

The Risks and Benefits of Benzadiazepines: A Balanced Update

Speaker: David V. Sheehan, MD, MBA

4:30 PM – 5:30 PM

Panel Discussion: Faculty and Audience

Panelists:

• Giuliana Altare, DNP, APRN, PMHNP-BC

• Sogol Javaheri, MD, MPH

• Luca Pani, MD

• David V. Sheehan, MD, MBA

• Roger D. Weiss, MD

Session titles follow the published official agenda, including its original spelling. Individual sessions, times, and faculty describe the original conference and do not independently confirm the contents of any separately offered video package.

Major Topics Covered

1. Precision Psychiatry and Personalized Psychopharmacology

• Personalized psychiatric treatment strategies

• Pharmacogenomics and genetic variability

• Psychotropic medication selection and sequencing

• Pharmacokinetic considerations and treatment optimization

• Individualized management of treatment-resistant psychiatric conditions

2. Neuroscience and Psychiatric Pathophysiology

• Neurobiological foundations of psychiatric disorders

• Psychiatric nosology and disease classification

• Neural circuits and psychiatric symptoms

• Inflammation and mood disorders

• Translating neuroscience research into clinical treatment

3. Depression, Bipolar Disorder, and Treatment Resistance

• Difficult-to-treat major depressive disorder

• Pharmacological approaches to mood disorders

• Innovations in antidepressant therapy

• Neuromodulation and emerging somatic interventions

• Psychedelics and investigational psychiatric treatments

• Individualized approaches to complex mood disorders

4. Pediatric and Adolescent Psychopharmacology

• Medication management in children and adolescents

• Developmental considerations in psychiatric treatment

• Age-appropriate prescribing and monitoring

• Evidence-based treatment innovations

• Clinical safety and treatment response

5. Women’s Mental Health and Geriatric Psychiatry

• Psychopharmacology across the female reproductive lifespan

• Hormonal influences on psychiatric treatment

• Psychiatric medication considerations during reproductive transitions

• Medication selection in older adults

• Geriatric psychiatric safety and tolerability

6. Autism Spectrum Disorder and Serious Mental Illness

• Neurobiological mechanisms in autism spectrum disorder

• Advances in pharmacological treatment research

• Emerging psychiatric therapeutic targets

• Digital phenotyping in serious mental illness

• Monitoring and assessment of psychiatric treatment outcomes

7. Artificial Intelligence in Psychiatric Care

• AI-assisted psychiatric assessment

• Genetics and artificial intelligence in personalized treatment

• Clinical applications of emerging digital technologies

• Algorithmic bias and data privacy

• Ethical considerations in AI-supported psychiatric decision-making

• Preserving patient-centered care and the therapeutic alliance

8. Sleep Disorders, Addiction, and Medication Safety

• Neurobiological mechanisms of sleep disturbances

• Pharmacological strategies for psychiatric sleep disorders

• Co-occurring psychiatric and substance use disorders

• Integrated approaches to dual diagnosis

• Benzodiazepine risks, benefits, and prescribing considerations

• Risk mitigation and clinical monitoring

Course Directors and Featured Faculty

The program includes faculty from the University of Miami and other academic institutions with expertise in psychopharmacology, neuroscience, psychiatric disorders, and clinical research.

Course Co-Directors

• Barbara J. Coffey, MD, MS

• Luca Pani, MD

Featured Faculty and Speakers

• Nassir Ghaemi, MD, MPH

• Ariadna Forray, MD

• Elizabeth Crocco, MD

• Philip Harvey, PhD

• Alexander Kolevzon, MD

• Gerard Sanacora, MD, PhD

• Daniel Weinberger, MD

• Charles Nemeroff, MD, PhD

• Alan Schatzberg, MD

• Azizi Seixas, PhD

• Sogol Javaheri, MD, MPH

• Roger D. Weiss, MD

• David V. Sheehan, MD, MBA

• Giuliana Altare, DNP, APRN, PMHNP-BC

Faculty participation is drawn from the official 2026 conference listing.

Why This Course Is Relevant

University of Miami Living Legends in Psychopharmacology 2026 addresses major challenges in contemporary psychiatric practice, particularly the need for personalized, evidence-based therapeutic strategies for patients with complex and treatment-resistant mental health conditions.

The program combines established clinical principles with new research in neuroscience, pharmacogenomics, digital phenotyping, precision psychiatry, and artificial intelligence.

Its multidisciplinary perspective is particularly valuable for psychiatrists, nurse practitioners, psychologists, and other mental health professionals seeking to understand how emerging discoveries may influence medication selection, therapeutic monitoring, and long-term psychiatric care.

The conference also emphasizes psychiatric treatment across different life stages, ethical clinical decision-making, and the importance of preserving a strong therapeutic alliance while adopting new technologies.

Short Description

SEO Information

Focus Keyword: University of Miami Living Legends in Psychopharmacology 2026

Additional SEO Keywords: Living Legends in Psychopharmacology 2026, University of Miami Psychiatry Conference, Psychopharmacology CME 2026, Advanced Psychopharmacology, Precision Psychiatry, Treatment-Resistant Depression, Psychiatric Pharmacogenomics, Artificial Intelligence in Psychiatry, Neuroscience and Mental Health, Emerging Psychiatric Treatments, Psychiatric Medication Management.

+ Topics:

• 01 New Vistas in the Treatment of Mood & Anxiety Disorders – Psychedelics, Neuromodulation and More
• 02 Young Brains Current Evidence and Innovations in Pediatric and Adolescent Psychopharmacology
• 03 Hormones and the Mind – Psychopharmacology Across the Female Reproductive Lifespan
• 04 Caring for the Aging Mind – Psychopharmacologic Approaches in Geriatric Psychiatry
• 05 Advances in Pharmacological Treatments in Serious Mental Illness – Decoding the Breadth of Treatment Effects With Accessible Digital Phenotyping
• 06 Beyond Behavior – Pharmacologic and Neurobiological Advances in Treating Autism Spectrum Disorder
• 07 From Mesmer to Psychedelics – Appreciating the Contributions of Contextual Factors to Treatment Response
• 08 Improving Outcomes in Treatment-Resistant Depression Through Personalized, Evidence-Based Strategies
• 08 Personalizing Psychopharmacology Through Genetics and Artificial Intelligence
• 09 From Synapse to Symptom to Disease – Nosology and Pathogenesis as the Foundation for Psychiatric Treatment
• 10 Depression Decoded – Inflammation, Neurocircuitry, and Breakthrough Treatments for Difficult-to-Treat Mood Disorders
• 11 Navigating the Future – Ethical Challenges and Considerations of Artificial Intelligence in Psychiatric Care
• 13 Restoring Rest – Neurobiological and Pharmacologic Strategies for Sleep Disorders in Psychiatric Practice
• 14 Dual Diagnosis in Focus – Treating Co-Occurring Psychiatric and Substance Use Disorders
• 15 The Risks and Benefits of Benzodiazepines – A Balanced Update